GHRS Quote, Financials, Valuation and Earnings

Iterum Therapeutics PLC has a net margin of -- compared to GH Research PLC's net margin of --. GH Research PLC's return on equity of -- beat Iterum Therapeutics PLC's return on equity of --.

GH Research PLC has a consensus price target of --, signalling upside risk potential of 346.43%. On the other hand Iterum Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 321.35%. Given that GH Research PLC has higher upside potential than Iterum Therapeutics PLC, analysts believe GH Research PLC is more attractive than Iterum Therapeutics PLC.

GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iterum Therapeutics PLC has a beta of 2.404, suggesting its more volatile than the S&P 500 by 140.42%.

GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Iterum Therapeutics PLC pays out -- of its earnings as a dividend.

GH Research PLC quarterly revenues are --, which are smaller than Iterum Therapeutics PLC quarterly revenues of --. GH Research PLC's net income of -$12.1M is lower than Iterum Therapeutics PLC's net income of -$7.1M. Notably, GH Research PLC's price-to-earnings ratio is -- while Iterum Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus 33.98x for Iterum Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of -- compared to GH Research PLC's net margin of 20.39%. GH Research PLC's return on equity of -- beat Jazz Pharmaceuticals PLC's return on equity of 12.28%.

GH Research PLC has a consensus price target of --, signalling upside risk potential of 346.43%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $181.05 which suggests that it could grow by 45.72%. Given that GH Research PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe GH Research PLC is more attractive than Jazz Pharmaceuticals PLC.

GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.191%.

GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

GH Research PLC quarterly revenues are --, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. GH Research PLC's net income of -$12.1M is lower than Jazz Pharmaceuticals PLC's net income of $215.1M. Notably, GH Research PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 17.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus 2.06x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Mural Oncology PLC has a net margin of -- compared to GH Research PLC's net margin of --. GH Research PLC's return on equity of -- beat Mural Oncology PLC's return on equity of --.

GH Research PLC has a consensus price target of --, signalling upside risk potential of 346.43%. On the other hand Mural Oncology PLC has an analysts' consensus of -- which suggests that it could grow by 396.45%. Given that Mural Oncology PLC has higher upside potential than GH Research PLC, analysts believe Mural Oncology PLC is more attractive than GH Research PLC.

GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mural Oncology PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mural Oncology PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Mural Oncology PLC pays out -- of its earnings as a dividend.

GH Research PLC quarterly revenues are --, which are smaller than Mural Oncology PLC quarterly revenues of --. GH Research PLC's net income of -$12.1M is higher than Mural Oncology PLC's net income of -$31.8M. Notably, GH Research PLC's price-to-earnings ratio is -- while Mural Oncology PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus -- for Mural Oncology PLC. Usually stocks with elevated PS ratios are considered overvalued.

Prothena Corp PLC has a net margin of -- compared to GH Research PLC's net margin of -6082.58%. GH Research PLC's return on equity of -- beat Prothena Corp PLC's return on equity of -23.56%.

GH Research PLC has a consensus price target of --, signalling upside risk potential of 346.43%. On the other hand Prothena Corp PLC has an analysts' consensus of $49.75 which suggests that it could grow by 224.53%. Given that GH Research PLC has higher upside potential than Prothena Corp PLC, analysts believe GH Research PLC is more attractive than Prothena Corp PLC.

GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prothena Corp PLC has a beta of 0.086, suggesting its less volatile than the S&P 500 by 91.418%.

GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prothena Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Prothena Corp PLC pays out -- of its earnings as a dividend.

GH Research PLC quarterly revenues are --, which are smaller than Prothena Corp PLC quarterly revenues of $970K. GH Research PLC's net income of -$12.1M is higher than Prothena Corp PLC's net income of -$59M. Notably, GH Research PLC's price-to-earnings ratio is -- while Prothena Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus 6.21x for Prothena Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.